Suppression of post-glucose hyperinsulinaemia does not affect blood pressure in either normotensive or hypertensive subjects

What Was Tested

Researchers studied Octreotide and Somatostatin in the context of low blood pressure and orthostatic hypotension in this randomized controlled trial publication.

Hyperinsulinaemia and insulin resistance are thought to be intimately involved in the development of hypertension, but controversy remains as to whether hyperinsulinaemia is a consequence or a cause of hypertension per se, and whether it plays a role in the short-term regulation of blood pressure. 2.

In one of these tests the endogenous insulin response was inhibited with subcutaneous octreotide. 3.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

The participants were allocated by chance, so the Octreotide group and the comparison group should start out alike.

The comparison arm used a placebo, so changes seen with Octreotide could be set against what happens without it.

What Was Measured

In one of these tests the endogenous insulin response was inhibited with subcutaneous octreotide. 3.

PubMed files the paper under topics including Case-Control Studies, Depression, Chemical, Glucose, Glucose Tolerance Test, Hypertension, Insulin and Norepinephrine.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Octreotide and Somatostatin in people with low blood pressure and orthostatic hypotension.

The publication is from 1998 (Clinical science (London, England : 1979)), a journal based in England.

More context: the Octreotide compound page and the Somatostatin compound page, Low blood pressure and orthostatic hypotension research.